Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ADMA Biologics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

12 Apr 2014 Reuters Investment Profile 12 $20.00

ADMA: 4Q13: 2014 will be the key year with major catalyst toward year-end; reiterating Buy rating and a 12-month price target of $15.00

ADMA reported 4Q13 financial results with a net loss of ($4.7MM), or ($0.55) net loss per share. For the 2014 full year, net...

01 Apr 2014 Laidlaw & Company 8 $25.00

ADMA: Continued confidence after recent management update; reiterating Buy rating and a 12-month price target of $15.00

After a recent company update by ADMA management, we walked away with renewed confidence as all the company’s development pla...

27 Jan 2014 Laidlaw & Company 8 $25.00

ADMA: RSV Prevention and Treatment in Immune-compromised Patient; initiation with a Buy rating and a 12-month price target of $15.00

With a modest hurdle for approval, substantial unmet need, limited competition and robust Phase II and real world use clinica...

21 Nov 2013 Laidlaw & Company 32 $75.00

Company Snapshot - Adma Biologics Inc

Four Directors at Adma Biologics Inc bought 108,939 shares at 8.500USD. The significance rating of the trade was 73/100. Is ...

24 Oct 2013 Directors Deals Ltd. 1 $12.00